A systems approach defining constraints of the genome architecture on lineage selection and evolvability during somatic cancer evolution

Cancer heterogeneity: converting a limitation into a source of biologic information

Analysis of spatial and temporal genetic heterogeneity in human cancers has revealed that somatic cancer evolution in most cancers is not a simple linear process composed of a few sequential steps of mutation acquisitions and clonal expansions. Parallel evolution has been observed in many early human cancers resulting in genetic heterogeneity as well as multilineage progression. Moreover, aneuploidy as well as structural chromosomal aberrations seems to be acquired in a non-linear, punctuated mode where most aberrations occur at early stages of somatic cancer evolution. At later stages, the cancer genomes seem to get stabilized and acquire only few additional rearrangements. While parallel evolution suggests positive selection of driver mutations at early stages of somatic cancer evolution, stabilization of structural aberrations at later stages suggests that negative selection takes effect when cancer cells progressively lose their tolerance towards additional mutation acquisition. Mixing of genetically heterogeneous subclones in cancer samples reduces sensitivity of mutation detection. Moreover, driver mutations present only in a fraction of cancer cells are more likely to be mistaken for passenger mutations. Therefore, genetic heterogeneity may be considered a limitation negatively affecting detection sensitivity of driver mutations. On the other hand, identification of subclones and subclone lineages in human cancers may lead to a more profound understanding of the selective forces which shape somatic cancer evolution in human cancers. Identification of parallel evolution by analyzing spatial heterogeneity may hint to driver mutations which might represent additional therapeutic targets besides driver mutations present in a monoclonal state. Likewise, stabilization of cancer genomes which can be identified by analyzing temporal genetic heterogeneity might hint to genes and pathways which have become essential for survival of cancer cell lineages at later stages of cancer evolution. These genes and pathways might also constitute patient specific therapeutic targets.

Nutrient-dependent growth defects and mutability of mutators in Escherichia coli

So-called mutators emerge when mismatch repair and proofreading mechanisms are defective. Mutators not only accelerate the accumulation of mutations that are beneficial for adaptation but also cause a large number of deleterious mutations that are disadvantageous for cell growth. However, such growth defects may be compensated by nutrient availability. How the growth burden is associated with high mutability in relation to nutritional variation is an intriguing question. To address this question, we constructed a variety of Escherichia coli mutator strains through combinatorial deletions of mismatch repair and proofreading genes and quantitatively evaluated their growth and mutation rates under different nutritional conditions. Growth defects caused by high mutation rates were commonly observed in all mutators, and these defects were alleviated by nutrient supplementation in most mutators. In addition, the mutation rates of the mutators fluctuated greatly in response to nutritional conditions, in contrast to the nearly constant mutation rate of the wild-type strain under varying nutritional conditions. The results showed conditional growth defects and nutrition-sensitive mutability as general features of mutators. This study indicates the importance of modulating mutability in response to changing nutrient conditions to minimize the risk of extinction due to genetic load.